Free tool
FAERS Monitor: Sucraid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020772 or its brand name (Sucraid, Sacrosidase). Reports on generic versions are filed under their own applications.
Reports
181
Serious
30
17% of reports
Hospitalization
14
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea36
- abdominal pain35
- drug ineffective22
- nausea21
- abdominal distension19
- flatulence17
- headache12
- product quality issue12
- dizziness11
- vomiting11
- fatigue9
- insomnia9
- constipation8
- product taste abnormal8
- decreased appetite7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 35 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 12 |
| 2023 | 31 |
| 2024 | 37 |
| 2025 | 25 |
| 2026 | 19 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,978 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product taste abnormalSignal | 8 | 68.7 | 34.9 | 468 |
| flatulenceSignal | 17 | 34.8 | 22.2 | 527 |
| abdominal distensionSignal | 19 | 21.2 | 13.8 | 347 |
| abdominal painSignal | 35 | 17.5 | 13.0 | 533 |
| product quality issueSignal | 12 | 10.3 | 5.9 | 92 |
| diarrhoeaSignal | 36 | 6.5 | 4.8 | 167 |
| constipationSignal | 8 | 4.3 | 2.2 | 17 |
| insomniaSignal | 9 | 3.9 | 2.1 | 17 |
| decreased appetiteSignal | 7 | 3.5 | 1.7 | 10 |
| nauseaSignal | 21 | 3.1 | 2.1 | 29 |
| vomitingSignal | 11 | 2.7 | 1.5 | 11 |
| dizzinessSignal | 11 | 2.6 | 1.4 | 9 |
| headacheSignal | 12 | 2.2 | 1.3 | 7 |
| drug ineffective | 22 | 1.9 | 1.3 | 10 |
| fatigue | 9 | 1.3 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.